In this single-arm, open-label, first-in-human phase I trial (NCT03980288), Fang and colleagues investigated the safety and anti-tumor activity of autologous 4G-CAR-GPC3 T-cells for patients with GPC3+ heavily pretreated advanced HCC. This evidence concerns the gene GPC3 and hepatocellular carcinoma.